Evidence map›Paper›PMID 40118609›Full record

ArticleJACC. Case reports2025

The Novel A-Flux Coronary Sinus Reducer Normalizes Coronary Microvascular Function in a Persistently Symptomatic Patient.

Giovanni Occhipinti, Anthony Salazar-Rodriguez, Francesco Giannini, Rishi Puri, Omar Abdul-Jawad Altisent, Ander Regueiro, Xavier Freixa, Eduardo Flores-Umanzor, Manel Sabaté, Salvatore Brugaletta

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giovanni OcchipintiHospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Anthony Salazar-RodriguezHospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Francesco GianniniDivision of Cardiology, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy.
Rishi PuriHeart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Omar Abdul-Jawad AltisentHospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Ander RegueiroHospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Xavier FreixaHospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Eduardo Flores-UmanzorHospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Manel SabatéHospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Salvatore BrugalettaHospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain. Electronic address: sabrugaletta@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronary microvascular dysfunction (CMD) contributes to persistent angina/anginal equivalent symptoms and is associated with adverse outcomes. Coronary sinus reduction (CSR) is a device-based therapy with the potential to improve outcomes by reducing symptom burden and improving coronary flow reserve. A patient with CMD underwent CSR with the next-generation A-Flux device.

Indexed as

A-Fluxcoronary artery diseasecoronary sinus reductionmicrovascular dysfunction

Identifiers

PMID40118609
PMCPMC12011155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.